Blood filtering to remove antibodies in people with long COVID
Tests immunoadsorption, a blood filtering treatment, in adults with antibody-related long COVID.
Plain-language title generated from the registry record
Registry title: Immunoadsorption in Autoimmune Long COVID
Key facts
- Where
- Amsterdam, NetherlandsSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07316127, who can take part
Where in Netherlands
- AUMCAmsterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Trial code
- NCT07316127
- Record updated
- 10 November 2026
- Original description
Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake.Read full original descriptionShow less
A Placebo-Controlled, Double-Blind, Randomized Trial Phase I-II With Immunoadsorption in Autoimmune Long COVID
Some people continue to have serious symptoms long after COVID-19, such as extreme fatigue and feeling worse after activity. In some patients, this may happen because the immune system is attacking the body by mistake.
This study will test a treatment called immunoadsorption, which filters the blood to remove harmful antibodies. People with long COVID who have these antibodies will be randomly assigned to receive either the real treatment or a placebo. The main goal is to see whether fatigue improves after one month, and whether other symptoms and daily functioning improve over six months.
This research will help us find out if this treatment can benefit the group of long COVID patients with immune-related disease.
Inclusion: Long COVID based on the WHO-criteria; PEM according to the DSQ-PEM; BELL's functionality score 20-70%; Good health prior to the long COVID diagnosis (WHO performance score 0).
Exclusion: Prior interventional cardiac procedure within 3 months prior to randomization; Poor performance score prior to the long COVID diagnosis (WHO performance >0); Medical history of clinically significant respiratory- or cardiovascular disease; Active immunosuppresive treatment for systemic autoimmune disorders; Diabetes type 1; Solid organ malignancy in the last 5 years; Active psychiatric disorder currently under treatment by a psychiatrist; BMI > 35; Pre-existing fatigue; Pregnancy or breastfeeding.